SavedAdd your journal

Journals / Journal of Health Sciences and Medicine / 2026 / Volume: 9 Issue: 2

‘LT3-treatment’ protocol of short-term hypothyroidism induction in patients with differentiated thyroid carcinoma: a safer strategy with lower risk of laboratory abnormalities compared to ‘no treatment’ protocol

Damla Tüfekçi(RECEP TAYYİP ERDOĞAN ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-5928-873X
Serap Baydur Şahin(BAHÇEŞEHİR ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-3944-136X
Teslime Ayaz(İZMİR BAKIRÇAY ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-3468-1428
Pages
—
Publication Date
2026-03-12
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In conclusion, ‘LT3 treatment strategy’ seems to have several advantages over ‘no treatment strategy’ during short-term hypothyroidism induction in terms of reducing the risk of laboratory abnormalities such as milder raise in serum creatinine, calcium and total cholesterol levels, while ensuring the effective stimulation of endogenous TSH levels sufficient for radioiodine therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: The utilization of levotriiodothyronine (LT3) during hypothyroidism induction remains relatively unexplored in patients with differentiated thyroid carcinoma (DTC).
📊
Key Findings & Data:This study aimed to compare laboratory findings for ‘non-treated’ versus ‘LT3 treated’ protocols of short-term hypothyroidism induction in patients with DTC.
💡
Conclusion & Impact:Conclusion: In conclusion, ‘LT3 treatment strategy’ seems to have several advantages over ‘no treatment strategy’ during short-term hypothyroidism induction in terms of reducing the risk of laboratory abnormalities such as milder raise in serum creatinine, calcium and total cholesterol levels, while ensuring the effective stimulation of endogenous TSH levels sufficient for radioiodine therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Differentiated thyroid carcinoma · levotriiodothyronine · hypothyroidism induction

Abstract

Aims: The utilization of levotriiodothyronine (LT3) during hypothyroidism induction remains relatively unexplored in patients with differentiated thyroid carcinoma (DTC). This study aimed to compare laboratory findings for ‘non-treated’ versus ‘LT3 treated’ protocols of short-term hypothyroidism induction in patients with DTC. Methods: A total of 130 patients with DTC who had thyroxine withdrawal to induce hypothyroid state prior to RAI ablation after initial surgery were included in this retrospective study. Patients were divided into two groups based on characteristics of thyroxine withdrawal period including those followed without treatment during the entire hypothyroidism induction period (non-treated group, n=67) and those followed with administration and then discontinuation of LT3 for the last 2 weeks of induction (LT3-treated group, n=63). Results: Not-treated vs. LT3-treated patients had significantly lower post-induction platelet counts (p=0.001) and smaller increase in platelet counts from baseline (p=0.005), higher increase from baseline total cholesterol (p=0.025), greater decrease in Ca from baseline (p=0.032), greater increase from baseline creatinine (p=0.041) and higher post-induction TSH (p=0.021). Conclusion: In conclusion, ‘LT3 treatment strategy’ seems to have several advantages over ‘no treatment strategy’ during short-term hypothyroidism induction in terms of reducing the risk of laboratory abnormalities such as milder raise in serum creatinine, calcium and total cholesterol levels, while ensuring the effective stimulation of endogenous TSH levels sufficient for radioiodine therapy.

🔖

Cite This Article

Tüfekçi, D., Şahin, S. B., Ayaz, T. (2026). ‘LT3-treatment’ protocol of short-term hypothyroidism induction in patients with differentiated thyroid carcinoma: a safer strategy with lower risk of laboratory abnormalities compared to ‘no treatment’ protocol. Journal of Health Sciences and Medicine, Volume: 9 Issue: 2. https://doi.org/10.32322/jhsm.1876737

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (25)

  1. Cirello V, Gambale C, Nikitski AV, Masaki C, Roque J, Colombo C. Poorly differentiated thyroid carcinoma: molecular, clinico-pathological hallmarks and therapeutic perspectives. Panminerva Med. 2024;66(2):155-173. doi:10.23736/S0031-0808.23.05040-1
  2. Sunny S, Graham K, Hephzibah J, Colville D. Radioactive iodine for differentiated thyroid carcinoma. Curr Opin Endocrinol Diabetes Obes. 2025;32(6):296-301. doi:10.1097/MED.0000000000000932
  3. Boucai L, Zafereo M, Cabanillas ME. Thyroid cancer: a review. JAMA. 2024;331(5):425-435. doi:10.1001/jama.2023.26348
  4. Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46(Suppl 1): 28S-37S.
  5. Filetti S, Durante C, Hartl D, et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(12):1856-1883. doi:10.1093/annonc/mdz400
  6. Botella-Carretero JI, Gómez-Bueno M, Barrios V, et al. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2004;11(2):345-356. doi:10.1677/erc.0. 0110345
  7. Yoo J, Cosby R, Driedger A. Preparation with recombinant humanized thyroid-stimulating hormone before radioiodine ablation after thyroidectomy: a systematic review. Curr Oncol. 2009;16(5):23-31. doi: 10.3747/co.v16i5.306
  8. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43(11):1482-1488.
  9. Kayano D, Taki J, Inaki A, et al. Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer. Asia Ocean J Nucl Med Biol. 2013;1(1):20-26. doi:10.7508/aojnmb.2013. 01.005
  10. Leboeuf R, Perron P, Carpentier AC, Verreault J, Langlois MF. L-T3 preparation for whole body scintigraphy: a randomized controlled trial. Clin Endocrinol (Oxf). 2007;67(6):839-844. doi:10.1111/j.1365-2265.2007. 02972.x
  11. Lee J, Yun MJ, Nam KH, Chung WY, Soh EY, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20(2):173-179. doi:10. 1089/thy.2009.0187
  12. McLaughlin CM, Hunter SJ, Bell PM, McCance DR, Sheridan B, Atkinson AB. Conventional withdrawal of thyroid hormone before radioiodine therapy in differentiated thyroid carcinoma: how frequently are adequately raised TSH levels attained? Clin Endocrinol (Oxf). 2008; 69(1):169-170. doi:10.1111/j.1365-2265.2007.03151.x
  13. Piccardo A, Puntoni M, Ferrarazzo G, et al. Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients? Eur J Nucl Med Mol Imaging. 2018;45(7):1218-1223. doi:10.1007/s00259-018-3955-x
  14. An JH, Song KH, Kim DL, Kim SK. Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer. J Int Med Res. 2017;45(1):38-50. doi:10.1177/0300060516664242
  15. Sigal GA, Tavoni TM, Silva BMO, Kalil Filho R, Brandão LG, Maranhão RC. Effects of short-term hypothyroidism on the lipid transfer to high-density lipoprotein and other parameters related to lipoprotein metabolism in patients submitted to thyroidectomy for thyroid cancer. Thyroid. 2019;29(1):53-58. doi:10.1089/thy.2018.0190
  16. Botella-Carretero JI, Alvarez-Blasco F, Sancho J, Escobar-Morreale HF. Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal. Thyroid. 2006;16(4):397-402. doi:10.1089/thy.2006.16.397
  17. Collet TH, Bauer DC, Cappola AR, et al. Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. J Clin Endocrinol Metab. 2014;99(9): 3353-3362. doi:10.1210/jc.2014-1250
  18. McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011;21(8): 837-843. doi:10.1089/thy.2010.0298
  19. Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010; 304(12):1365-1374. doi:10.1001/jama.2010.1361
  20. Massolt ET, Salih M, Beukhof CM, et al. Effects of thyroid hormone on urinary concentrating ability. Eur Thyroid J. 2017;6(5):238-242. doi:10. 1159/000478521
  21. Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol. 2010;23(1):22-26. doi:10.1681/ASN.2010070766
  22. Hammami MM, Alsaihati B, Alahmari S, Alnuaim AA, Khan BA. Elevated serum creatinine level in thyroid cancer patients undergoing withdrawal of thyroxine therapy for radioiodine scan/treatment. Ann Saudi Med. 1995;15(4):358-362. doi:10.5144/0256-4947.1995.358
  23. Matsuoka-Uchiyama N, Tsuji K, Takahashi K, et al. Association between urinary creatinine excretion and hypothyroidism in patients with chronic kidney disease. Diagnostics (Basel). 2023;13(4):669. doi:10.3390/diagnostics13040669
  24. Tufekci D, Ayaz T, Sahin SB, Hocaoglu C. The "non-treated" versus "LT3-treated" protocols of short-term hypothyroidism induction in differentiated thyroid cancer: an analysis of hypothyroid complications, mood disorders, and quality of life. Horm Metab Res. 2023;55(7):462-470. doi:10.1055/a-2056-6073
  25. Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012; 366(18):1663-1673. doi:10.1056/NEJMoa1108586